Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia
Grzegorz Helbig(Medical University of Silesia), Sławomira Kyrcz‐Krzemień(Medical University of Silesia), Andrzej Moskwa, Ilona Seferyńska, Jarosław Piszcz(Medical University of Białystok), Małgorzata Raźny, Ewa Żuk(University of Szczecin), Małgorzata Całbecka(Provincial Polyclinical Hospital in Toruń), Alina Urbanowicz, Alina Świderska(University of Zielona Góra), Marek Rodzaj, Marek Hus(Medical University of Lublin)
Cited by 24
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70